+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the impact of ultra-early transnasal evaporative cooling after cardiac arrest followed by hypothermia in hospital on survival with full neurological recovery. This trial compares this cooling method to the standard treatment of maintaining normal body temperature normothermia in adults aged 18 to 79 who experience out-of-hospital cardiac arrest with an initial shockable heart rhythm. The main goal is to determine if early cooling improves survival with good brain function 90 days after the cardiac arrest. Participants are randomly assigned to one of two groups. One group receives the early transnasal evaporative cooling started by emergency medical services EMS at the scene within 20 minutes of arrival, followed by systemic cooling to 33C for 24 hours and fever control for 72 hours in intensive care. The other group receives standard advanced cardiac life support and fever control to maintain normal body temperature for 72 hours in intensive care. Both approaches are monitored closely during hospital care. During the study, participants are observed for survival and neurological recovery up to 90 days after cardiac arrest. Researchers assess outcomes such as return of spontaneous circulation, survival at hospital discharge, and neurological status using the modified Rankin scale. Safety is monitored by tracking device-related and serious adverse events within the first week. This study runs from March 2024 to May 2028 and is sponsored by Karolinska Institutet.

Age: 18Years - 79YearsAll GendersPhase Not Applicable
17 locations